Amgen has agreed to buy U.K. blood cancer biotech Dark Blue Therapeutics in a deal worth up to $840 million.
Why it matters: The deal bolsters Amgen's oncology pipeline, adding Dark Blue's investigational small molecule to treat specific types of acute myeloid leukemia.
